Anthera Pharmaceuticals, Inc. (ANTH) At $1.83 Forms Bottom; Ansys (ANSS) Sellers Decreased By 3.9% Their Shorts

Ansys Incorporated (NASDAQ:ANSS) had a decrease of 3.9% in short interest. ANSS’s SI was 1.37M shares in January as released by FINRA. Its down 3.9% from 1.43 million shares previously. With 607,700 avg volume, 2 days are for Ansys Incorporated (NASDAQ:ANSS)’s short sellers to cover ANSS’s short positions. The stock increased 0.14% or $0.22 during the last trading session, reaching $161.76. About 22,291 shares traded. Ansys, Inc. (NASDAQ:ANSS) has risen 43.75% since January 25, 2017 and is uptrending. It has outperformed by 27.05% the S&P500.

Anthera Pharmaceuticals, Inc. (ANTH) formed multiple bottom with $1.74 target or 5.00% below today’s $1.83 share price. Anthera Pharmaceuticals, Inc. (ANTH) has $25.35 million valuation. The stock decreased 2.14% or $0.04 during the last trading session, reaching $1.83. About 249,376 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 93.94% since January 25, 2017 and is downtrending. It has underperformed by 110.64% the S&P500.

Among 6 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Anthera Pharmaceuticals has $15 highest and $1.35 lowest target. $6.20’s average target is 238.80% above currents $1.83 stock price. Anthera Pharmaceuticals had 17 analyst reports since August 13, 2015 according to SRatingsIntel. On Wednesday, September 9 the stock rating was initiated by Suntrust Robinson with “Buy”. As per Tuesday, September 12, the company rating was maintained by Jefferies. On Monday, January 22 the stock rating was maintained by Piper Jaffray with “Buy”. As per Sunday, August 6, the company rating was maintained by Jefferies. The company was upgraded on Thursday, August 13 by Zacks. The firm has “Buy” rating given on Thursday, December 29 by H.C. Wainwright. The company was initiated on Thursday, September 17 by Citigroup. The firm has “Buy” rating given on Wednesday, September 9 by SunTrust. The rating was downgraded by Citigroup to “Neutral” on Thursday, December 29. On Friday, February 19 the stock rating was reinitiated by Jefferies with “Buy”.

Analysts await Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report earnings on February, 26. They expect $-0.82 EPS, up 71.53% or $2.06 from last year’s $-2.88 per share. After $-0.58 actual EPS reported by Anthera Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 41.38% negative EPS growth.

Among 15 analysts covering Ansys Inc. (NASDAQ:ANSS), 2 have Buy rating, 2 Sell and 11 Hold. Therefore 13% are positive. Ansys Inc. had 34 analyst reports since August 6, 2015 according to SRatingsIntel. As per Thursday, September 14, the company rating was maintained by J.P. Morgan. KeyBanc Capital Markets maintained the shares of ANSS in report on Wednesday, September 27 with “Hold” rating. The stock of Ansys, Inc. (NASDAQ:ANSS) earned “Buy” rating by Robert W. Baird on Friday, November 3. The company was maintained on Tuesday, February 16 by Wedbush. The stock of Ansys, Inc. (NASDAQ:ANSS) has “Equal Weight” rating given on Thursday, October 8 by Pacific Crest. The firm has “Buy” rating by Robert W. Baird given on Monday, August 28. Needham maintained Ansys, Inc. (NASDAQ:ANSS) on Friday, September 15 with “Hold” rating. Barclays Capital maintained it with “Equal-Weight” rating and $94 target in Friday, August 5 report. The company was maintained on Friday, September 15 by Barclays Capital. Goldman Sachs initiated the stock with “Hold” rating in Monday, July 17 report.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: